Brophy Michael Burkes, the Chief Financial Officer of Natera, Inc., has reported the sale of 795 shares of the company. This transaction is significant as it reflects the structured approach executives often take when managing their stock holdings.

The sales were executed on November 2 and 3, 2026, and were part of a Rule 10b5-1 trading plan. This type of plan allows executives to set up a predetermined schedule for selling shares, which can help avoid any potential issues related to insider trading. The filing indicates that the sales were made to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).

Background

Natera, Inc. is a prominent player in the medical laboratories sector, which is classified under the Standard Industrial Classification (SIC) code 8071. The company is known for its innovative genetic testing services aimed at improving patient care. Natera's stock is traded under the ticker symbol NTRA.

What the Filing Says

According to the filing, Burkes sold 8 shares at a price of $388.03 each and 317 shares at $400.29 each on November 2, 2026. Additionally, he sold 470 shares at $391.49 each on November 3, 2026. Following these transactions, Burkes retained a total of 45,779 shares of Natera.

Impact

The transactions may affect Burkes' financial standing and reflect his ongoing commitment to managing his shareholdings responsibly. The structured nature of these sales, as outlined in the filing, indicates a proactive approach to compliance with securities regulations.

What's Next

The filing does not say what happens next.